Are you considering SBRT in your prostate cancer patients who had a RP and now have a rising PSA and oligometastatic bone disease?

Yes, we offer SBRT for oligometastatic disease, with a frank discussion of current understanding of the potential benefits and risks. We await results of phase III trials, but smaller trials have been encouraging for a progression-free survival benefit (SABR-COMET, STOMP, ORIOLE).